KOSDAQBiotech & Pharma373110

Xcell Therapeutics

₩619▼ 17.02%2026-11-18 close
Market Cap
₩10.7B
Turnover
₩100M
Volume
180K
Shares out.
17.3M
PER
—
PBR
—
EPS
-₩753
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales recovering, but operating losses persist

Quarterly sales have reached the KRW 1 billion level in 2026, but operating losses have continued for five straight quarters, so whether sales recovery translates into better profitability is the key point to watch.

  1. 1

    Third-quarter 2026 sales were KRW 1.06 billion, up 217.9% from a year earlier, yet the operating loss widened to KRW 2.98 billion from the prior quarter.

  2. 2

    Annual sales in 2025 were KRW 1.95 billion, up only 0.8%, while the operating loss widened to KRW 10.9 billion.

  3. 3

    The overseas share of product sales rose from 18.3% in 2024 to 35.4% in 2025, alongside expanding partnerships in China, the Middle East and Japan.

  4. 4

    The planned launch of four new media products within 2026 and efforts to apply its media to Cartistem in Japan are cited as medium-term growth drivers.

  5. 5

    Total equity at the end of 2025 was KRW 714 million, the debt ratio was 120.2%, and operating cash flow in 2025 was negative KRW 9.5 billion, leaving limited financial headroom.

02

Business structure

Xcell Therapeutics is a cell culture media specialist for cell and gene therapies (CGT), founded in 2015. Culture media supply the nutrients cells need to grow, and the company positions its third-generation chemically defined media (AOF), designed without animal-derived components, as its core technology.

Its flagship CellCor brand centers on MSC media for stem cell therapies and is expanding into exosome and T-cell and NK-cell lines.

Dedicated T-cell and NK-cell media were launched in 2026, and in a September 2026 announcement the company said four products (exosome, T-cell, NK-cell and MSC media) will be released in sequence within 2026. Its customers are mainly Korean stem cell therapy developers and Chinese cell therapy companies.

In China it holds an exclusive supply contract for T-cell and NK-cell media with a hyaluronic acid raw-material supplier, and it signed an exosome media supply deal and a domestic distribution agreement for recombinant human collagen with Shangya Bio.

In Japan it is pursuing application of CellCor media in the commercialization of Cartistem. Beyond media, a distribution business for overseas bio reagents and cell analysis equipment has been reported to generate roughly KRW 1 billion per quarter since late 2025.

The overseas share of product sales rose from 18.3% in 2024 to 35.4% in 2025. On competition, reports say the company's results fell short of expectations against imported media, and the company points to its chemically defined media technology as a differentiator.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩300M-₩2.4B−709.9%
2025Q4₩1.1B-₩3.3B−306.2%
2026Q1₩1B-₩2.9B−285.2%
2026Q2₩1.9B-₩2.8B−142.2%
2026Q3₩1.1B-₩3B−280.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1B-₩8.3B-₩8.3B−813.6%−98.3%82.8%
2023₩1.1B-₩8.7B-₩9.3B−774.6%−389.4%339.2%
2024₩1.9B-₩9.3B-₩9.5B−482.3%−104.6%85.2%
2025₩1.9B-₩10.9B-₩10.9B−556.8%−153.1%120.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed annual basis, sales were KRW 1.02 billion in 2022, KRW 1.12 billion in 2023 (up 10.2% year on year), KRW 1.93 billion in 2024 (up 72.1%) and KRW 1.95 billion in 2025 (up 0.8%). Sales rose three years in a row from 2023 through 2025, but the 2025 gain of 0.8% left top-line growth nearly flat.

Over the same period the operating loss was KRW 8.3 billion in 2022, KRW 8.71 billion in 2023, KRW 9.33 billion in 2024 and KRW 10.9 billion in 2025, a loss in each of four years with the size growing every year.

The operating margin improved from -813.6% in 2022 to -482.3% in 2024 before slipping back to -556.8% in 2025. The net loss attributable to controlling shareholders was KRW 10.9 billion in 2025, and the consolidated net loss including non-controlling interests was also KRW 10.9 billion.

The debt ratio moved widely, from 82.8% in 2022 to 339.2% in 2023, 85.2% in 2024 and 120.2% in 2025. At the end of 2025 total equity was KRW 7.14 billion and total liabilities were KRW 8.58 billion. Operating cash flow went from negative KRW 7.3 billion in 2022 to negative KRW 9.5 billion in 2025.

Media reports attributed the flat 2025 sales to delays in research schedules at major cell therapy customers.

On a quarterly basis, sales rose from KRW 335 million in the third quarter of 2025 to KRW 1.06 billion in the fourth quarter (up 217.8% from the prior quarter), then moved to KRW 1.02 billion in the first quarter of 2026, KRW 1.94 billion in the second and KRW 1.06 billion in the third.

The operating loss widened from KRW 2.38 billion in the third quarter of 2025 to KRW 3.26 billion in the fourth, then ran at KRW 2.91 billion, KRW 2.75 billion and KRW 2.98 billion through the third quarter of 2026.

Even in the second quarter of 2026, the strongest sales quarter, the operating loss was KRW 2.75 billion, so higher sales did not translate into a smaller loss. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 12.1 billion. A rights offering of KRW 9.5 billion to existing shareholders was carried out in November 2025.

05

Industry analysis

The expansion of the cell and gene therapy market underpins demand for culture media.

The company estimates China's cell therapy market at roughly KRW 4 trillion and says that capturing about 1% of it as raw-material media sales could support revenue of several hundred billion won a year; this is the company's own estimate.

For the Middle East, a market study cited in reports projects the UAE CGT market to grow at a mid-teens annual rate through 2030 and reach more than KRW 150 billion.

In Korea, the government is encouraging use of domestic bio materials, and an analyst report from August 2026 argued that the planned raw-material certification system would increase demand for domestic inputs. At this stage, the CGT media market is in an early phase in which product references are still being built.

The company says it completed the first US FDA DMF registration for a Korean mesenchymal stem cell chemically defined medium, and it is pursuing Japanese PMDA certification. However, imported products hold a large share of the global media market, and reports say results against imports have been slow.

Because order timing depends on customers' research and clinical schedules, quarterly sales are volatile, a feature of this industry.

06

Outlook

The company set a 2026 sales target of KRW 10 billion and aimed for more than KRW 3 billion from overseas exports alone, according to an April 2026 media report. Adding up disclosed sales from the first through third quarters of 2026 gives roughly KRW 4 billion, which is the yardstick for progress against that target.

On new products, the company said that as of its September 2026 announcement all four products had completed process development and were being transferred to its production unit; it has secured a Chinese bio company as a main customer and distributor for the exosome media and a Chinese hyaluronic acid raw-material supplier for the T-cell media.

Applying CellCor media to the Japanese commercialization of Cartistem was made official in June 2026.

On production, the company was selected for a government-backed raw-material manufacturing program to automate filling and packaging and expand capacity by about 2.5 times, with the project running through the end of 2027.

In China, in June 2026 the company began joint development of standard stem cell culture processes and EV manufacturing processes with a Chinese cell therapy research institute, and it is reported to be discussing a local production setup.

In the Middle East, it secured a base through a CellCor distribution agreement with a UAE distributor. Through the exclusive domestic distribution rights for Shangya's recombinant collagen, the company said it aims for more than KRW 50 billion in sales within five years (a company target).

Whether each of these items converts into quarterly sales will become visible in the 2026 annual report, the next regular filing.

07

Valuation

PER
—
PBR
—
ROE
-837.1%
EPS
-₩753
BPS
—
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated. With no earnings-based multiple available, the more usable comparison is between market capitalization and total equity.

Market capitalization sits above total equity, which means the stock trades at a premium to book value. Total equity at the end of 2025 was a thin base, and the debt ratio rose from 82.8% in 2022 to 120.2% in 2025, so the debt load relative to equity has grown.

No dividend is paid, so the dividend yield is 0%, and there is currently no cash return mechanism for shareholders. On October 12, 2026, the Korea Exchange issued a notice flagging the stock as a possible administrative issue because its market capitalization is below KRW 20 billion.

The three-year grace period for the deficit-related administrative designation ends at the close of 2026, so market capitalization and capital base are both under scrutiny for listing maintenance.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Recovery in quarterly sales

Second-quarter 2026 sales were KRW 1.94 billion and third-quarter sales were KRW 1.06 billion, up 217.9% from a year earlier. Independent research firm Valuefinder's August 2026 report put first-half sales at about KRW 3 billion, up 438% year on year, and attributed the gain mainly to higher product sales. Quarterly sales have stayed around the KRW 1 billion level or above since the fourth quarter of 2025.

Overseas sales and partner expansion

The overseas share of product sales rose from 18.3% in 2024 to 35.4% in 2025.

Partner relationships are widening, including an exclusive supply deal for T-cell and NK-cell media with a Chinese hyaluronic acid supplier, exosome media and collagen distribution deals with Shangya Bio, and a supply agreement with a Mitsubishi Group affiliate in Japan. In the Middle East, a CellCor distribution agreement with a UAE distributor established a first local base.

New products and government-backed capacity

Four media products covering exosome, T-cell, NK-cell and MSC applications are scheduled for sequential launch within 2026, with process development reported as complete. The company was selected in April 2026 for a government raw-material manufacturing program that aims to expand capacity about 2.5 times.

Analysts noted that the planned use of its media in Cartistem could make it the first case of a domestically developed medium used in a commercial CGT product.

09

Bear factors

Persistent and widening operating losses

The 2025 operating loss widened to KRW 10.9 billion, with an operating margin of -556.8%. The third-quarter 2026 operating loss of KRW 2.98 billion was larger than in the prior quarter, and operating losses have continued for five straight quarters from the third quarter of 2025.

Thin capital base and cash burn

Total equity at the end of 2025 was KRW 714 million against total liabilities of KRW 858 million, and the debt ratio stood at 120.2%. Operating cash flow deteriorated from negative KRW 7.3 billion in 2022 to negative KRW 9.5 billion in 2025.

A KRW 9.5 billion rights offering in November 2025 added funds, but reports put cash and equivalents at about KRW 6 billion at the end of the first quarter of 2026.

Stalled sales and customer concentration

Sales went from KRW 1.93 billion in 2024 to KRW 1.95 billion in 2025, a 0.8% increase that amounts to a stall. Media reports attributed the weak demand to research schedule delays at major cell therapy customers.

Quarterly sales in 2026 have swung around the KRW 1 billion mark, and third-quarter 2026 sales fell 45.1% from the prior quarter. Reports also say results against imported media have been slow.

10

Risk factors

Listing maintenance requirements

The grace period for the administrative designation tied to pre-tax continuing operating losses ends at the close of 2026. From 2027, two or more such losses exceeding 50% of equity over three years could trigger a designation.

On October 12, 2026 the exchange flagged the stock because its market capitalization fell below KRW 20 billion. Listing maintenance thus depends on both earnings and capital size.

Funding needs and shareholder dilution

The company plans to deploy the KRW 9.5 billion raised in its November 2025 rights offering through 2027 across R&D, personnel, commercialization and facilities. If operating losses continue, further fundraising could dilute existing shareholders.

The gap between planned and actual spending will become visible in the cash flow statement of the next regular report.

Reliance on overseas partners and policy

Much of the sales expansion strategy depends on Chinese partners increasing orders and on discussions over local production. Changes in partners' purchase timing or in the regulatory environment could affect overseas sales expectations.

Government support and domestic-material incentives are tailwinds, but their scope and duration depend on policy.

11

What to watch next

  1. By end of December 2026

    Whether all four media products are launched within 2026 and whether supply to Chinese partners begins to show up in sales.

  2. End of December 2026

    Expiry of the grace period for the deficit-related administrative designation, after which the loss ratio and market capitalization tests will apply.

  3. By late March 2027 (statutory filing deadline)

    The 2026 annual report will show full-year sales, operating loss and operating cash flow, and how close sales came to the KRW 10 billion target.

  4. End of 2027

    Completion of the government-backed manufacturing program and whether production capacity is actually expanded about 2.5 times.

12

Overall view

Xcell Therapeutics has built a specialized position in cell culture media, and quarterly sales reached the KRW 1 billion level in 2026, but operating losses have run for five straight quarters and no earnings turnaround has appeared yet.

Sales rose three years in a row from 2023 through 2025, but growth slowed to 0.8% in 2025, while the operating loss has been recorded in each of four years from 2022 through 2025 and has grown.

Bullish factors include a higher overseas share of product sales (18.3% in 2024 rising to 35.4% in 2025), wider partnerships in China, the Middle East and Japan, and the planned four new products and Cartistem media application.

Bearish factors include the wider operating loss in the third quarter of 2026, limited financial capacity given a debt ratio of 120.2% and operating cash flow of negative KRW 9.5 billion in 2025, and listing risk tied to the deficit-related designation and market capitalization test.

The gap between the company's KRW 10 billion 2026 sales target and roughly KRW 4 billion in disclosed sales for the first three quarters will be clearer once full-year results are available.

The next checkpoints are the expiry of the grace period at the end of 2026 and the 2026 annual report's full-year operating margin and fourth-quarter sales trend. This report contains no investment opinion and is provided for information based on disclosed figures and scheduled events.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. supple.kr
  2. mt.co.kr
  3. bloter.net
  4. m.news.nate.com
  5. view.asiae.co.kr
  6. thebionews.net
  7. xcell.co.kr
  8. pharm.edaily.co.kr
  9. saramin.co.kr
  10. butler.works
  11. view.asiae.co.kr
  12. m.news.nate.com
  13. m.news.nate.com
  14. view.asiae.co.kr
  15. m.news.nate.com
  16. m.news.nate.com
  17. view.asiae.co.kr
  18. thebionews.net

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis